Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy

Jaren W. Landen, Sharon Cohen, Clare B. Billing, Carol Cronenberger, Scot Styren, Aaron H. Burstein, Catherine Sattler, Jae Hong Lee, Clifford R. Jack, Kejal Kantarci, Pamela F. Schwartz, William T. Duggan, Qinying Zhao, Ken Sprenger, Martin M. Bednar, Brendon Binneman

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Introduction Multiple intravenous doses of ponezumab, an anti-amyloid antibody, were evaluated in subjects with mild-to-moderate Alzheimer's disease (AD). Methods In part A, 77 subjects were randomized to ponezumab 0.1, 0.5, or 1 mg/kg (75 treated) and 26 to placebo (24 treated). In part B, 63 subjects were randomized and treated with ponezumab 3 or 8.5 mg/kg and 32 with placebo. Subjects received 10 infusions over 18 months and were followed for 6 months thereafter. Results Ponezumab was generally safe and well tolerated. Most common adverse events were fall (16.7% ponezumab, 21.4% placebo), headache (13.8%, 21.4%), and cerebral microhemorrhage (13.8%, 19.6%). Plasma ponezumab increased dose-dependently with limited accumulation. Cerebrospinal fluid penetration was low. Plasma Aβ1–x and Aβ1–40 showed robust increases, but cerebrospinal fluid biomarkers showed no dose response. Ponezumab had no effects on cognitive/functional outcomes or brain volume. Conclusions Multiple-dose ponezumab was generally safe, but not efficacious, in mild-to-moderate AD.

Original languageEnglish (US)
Pages (from-to)339-347
Number of pages9
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Issue number3
StatePublished - Sep 2017


  • Alzheimer's disease
  • Amyloid β
  • Biomarkers
  • Cerebrospinal fluid
  • Immunotherapy
  • Monoclonal antibody
  • Pharmacodynamics
  • Pharmacokinetics
  • Phase-II study
  • Ponezumab

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health


Dive into the research topics of 'Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy'. Together they form a unique fingerprint.

Cite this